Yaron Carmi promoted to Associate Professor


07 May 2024

Prof. Yaron Carmi, Department of Pathology, completed his PhD studies summa cum laude at Ben-Gurion University of the Negev and won the Pratt award for excellence PhD students. He completed his postdoctoral training at the Department of Immunology at Stanford University, where he earned the Young Investigator Award.


His work on dendritic cell vaccination was published in Nature and Cell and he has co-authored manuscripts in peer-reviewed journals, including Science and Immunity, and written four patents. Based on his findings, he co-founded two companies, Bolt Therapeutics and more recently, Gilboa Therapeutics, and he serves as a consultant in Velocity Pharmaceutical Development venture capital, and as a board member at the Israel Society for Gene and Cell Therapy.


Carmi was awarded the Alon Fellowship for outstanding young Israeli scientists. Prof. Carmi's research focuses on cancer immunotherapy. His team is using advanced microscopy and genetic engineering to monitor, in real time, how our immune cells communicate with each other. He is using the new understanding to develop better, safer therapies that kick in the natural anti-cancer immune response.

Tel Aviv University makes every effort to respect copyright. If you own copyright to the content contained
here and / or the use of such content is in your opinion infringing, Contact us as soon as possible >>